{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:43:07Z","timestamp":1794361387140,"version":"4.9.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["Funding of the writing of the manuscript"],"award-info":[{"award-number":["Funding of the writing of the manuscript"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006382","name":"Universidad de Oviedo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02192-y","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T16:36:55Z","timestamp":1746981415000},"page":"867-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Navigating Psoriatic Arthritis: Treatment Pathways and Patient-Specific Strategies for Improved Outcomes"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Queiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Pinto-Tasende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montilla-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"issue":"1","key":"2192_CR1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12955-020-01422-z","volume":"18","author":"LC Coates","year":"2020","unstructured":"Coates LC, Orbai AM, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18(1):173.","journal-title":"Health Qual Life Outcomes"},{"issue":"21","key":"2192_CR2","first-page":"2095","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"2192_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251\u201365 (e19).","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2192_CR4","volume":"15","author":"A Romero Perez","year":"2020","unstructured":"Romero Perez A, Queiro R, Seoane-Mato D, Graell E, Chamizo E, Chaves Chaparro L, et al. Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. PLoS\u00a0One. 2020;15(6): e0234556.","journal-title":"PLoS\u00a0One"},{"issue":"10136","key":"2192_CR5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"1","key":"2192_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2192_CR7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"2192_CR8","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1080\/1744666X.2023.2249235","volume":"19","author":"R Queiro","year":"2023","unstructured":"Queiro R, Loredo M, Brana I, Pardo E, Alonso S, Alperi M. Managing psoriatic arthritis in different clinical scenarios. Expert Rev Clin Immunol. 2023;19(12):1469\u201384.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"2192_CR9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2192_CR10","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101692","volume":"35","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021;35(2): 101692.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2192_CR11","doi-asserted-by":"crossref","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Korswagen LA, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10(1):e004062.","DOI":"10.1136\/rmdopen-2023-004062"},{"key":"2192_CR12","first-page":"1759720X2412667","volume":"16","author":"O Hen","year":"2024","unstructured":"Hen O, Harrison SR, De Marco G, Marzo-Ortega H. Early psoriatic arthritis: when is the right time to start advanced therapy? Ther Adv Musculoskelet Dis. 2024;16:1759720X241266727.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"2192_CR13","first-page":"1","volume":"7","author":"F Caso","year":"2024","unstructured":"Caso F, Costa L, Megna M, Cascone M, Maione F, Giacomelli R, et al. Early psoriatic arthritis: clinical and therapeutic challenges. Expert Opin Investig Drugs. 2024;7:1\u201321.","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"2192_CR14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/14712598.2023.2273269","volume":"23","author":"M Loredo","year":"2023","unstructured":"Loredo M, Brana I, Queiro R. Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients? Expert Opin Biol Ther. 2023;23(12):1159\u201362.","journal-title":"Expert Opin Biol Ther"},{"key":"2192_CR15","volume":"8","author":"SR Pennington","year":"2021","unstructured":"Pennington SR, FitzGerald O. Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis. Front Med (Lausanne). 2021;8: 723944.","journal-title":"Front Med (Lausanne)."},{"issue":"1","key":"2192_CR16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/art.42288","volume":"75","author":"A Paine","year":"2023","unstructured":"Paine A, Brookes PS, Bhattacharya S, Li D, De La Luz G-H, Tausk F, Ritchlin C. Dysregulation of bile acids, lipids, and nucleotides in psoriatic arthritis revealed by unbiased profiling of serum metabolites. Arthritis Rheumatol. 2023;75(1):53\u201363.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2192_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/rheumatology\/keae399","volume":"64","author":"C Lopez-Medina","year":"2025","unstructured":"Lopez-Medina C, McGonagle D, Gossec L. Subclinical psoriatic arthritis and disease interception-where are we in 2024? Rheumatology (Oxford). 2025;64(1):56\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2192_CR18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063650","volume":"12","author":"RH Haberman","year":"2022","unstructured":"Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12): e063650.","journal-title":"BMJ Open"},{"issue":"4","key":"2192_CR19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41584-021-00578-2","volume":"17","author":"LM Perez-Chada","year":"2021","unstructured":"Perez-Chada LM, Haberman RH, Chandran V, Rosen CF, Ritchlin C, Eder L, et al. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nat Rev Rheumatol. 2021;17(4):238\u201343.","journal-title":"Nat Rev Rheumatol"},{"key":"2192_CR20","doi-asserted-by":"crossref","unstructured":"Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023; 82(9):1162\u201370.","DOI":"10.1136\/ard-2023-224148"},{"key":"2192_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead621","author":"L Watson","year":"2023","unstructured":"Watson L, Coyle C, Whately-Smith C, Brooke M, Kiltz U, Lubrano E, et al. An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis. Rheumatology (Oxford). 2023. https:\/\/doi.org\/10.1093\/rheumatology\/kead621.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2192_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105469","volume":"90","author":"L Coates","year":"2022","unstructured":"Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences. Joint Bone Spine. 2022;90(1): 105469.","journal-title":"Joint Bone Spine"},{"key":"2192_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae163.202","author":"MA Brown","year":"2024","unstructured":"Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials. Ann Rheum Dis. 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae163.202.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2192_CR24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-022-00443-y","volume":"9","author":"LC Coates","year":"2022","unstructured":"Coates LC, de Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie AR. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence. Rheumatol Ther. 2022;9(3):803\u201321.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"2192_CR25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40744-022-00435-y","volume":"9","author":"P Richette","year":"2022","unstructured":"Richette P, Coates LC, Azevedo VF, Cappelleri JC, Moser J, Queiro-Silva R, et al. Patient perception of medical care for psoriatic arthritis in North America and Europe: results from a global patient survey. Rheumatol Ther. 2022;9(3):823\u201338.","journal-title":"Rheumatol Ther."},{"issue":"9","key":"2192_CR26","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00296-021-04877-5","volume":"41","author":"R Garcia-Vicuna","year":"2021","unstructured":"Garcia-Vicuna R, Garrido N, Gomez S, Joven B, Queiro R, Ramirez J, et al. Management of particular clinical situations in psoriatic arthritis: an expert\u2019s recommendation document based on systematic literature review and extended Delphi process. Rheumatol Int. 2021;41(9):1549\u201365.","journal-title":"Rheumatol Int"},{"issue":"28","key":"2192_CR27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016400","volume":"98","author":"R Queiro","year":"2019","unstructured":"Queiro R, Lorenzo A, Tejon P, Coto P, Pardo E. Obesity in psoriatic arthritis: comparative prevalence and associated factors. Medicine (Baltimore). 2019;98(28): e16400.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2192_CR28","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaad.2021.02.019","volume":"84","author":"JM Gelfand","year":"2021","unstructured":"Gelfand JM, Wan J, Zhang H, Shin DB, Ogdie A, Syed MN, Egeberg A. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study. J Am Acad Dermatol. 2021;84(6):1636\u201343.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2192_CR29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13075-020-02350-5","volume":"22","author":"E Klingberg","year":"2020","unstructured":"Klingberg E, Bjorkman S, Eliasson B, Larsson I, Bilberg A. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020;22(1):254.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2192_CR30","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13(5): e0195123.","journal-title":"PLoS ONE"},{"issue":"3","key":"2192_CR31","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217251","volume":"81","author":"I Pantano","year":"2022","unstructured":"Pantano I, Iacono D, Favalli EG, Scalise G, Costa L, Caso F, et al. Secukinumab efficacy in patients with PsA is not dependent on patients\u2019 body mass index. Ann Rheum Dis. 2022;81(3): e42.","journal-title":"Ann Rheum Dis"},{"key":"2192_CR32","volume":"8","author":"S Alonso","year":"2021","unstructured":"Alonso S, Villa I, Fernandez S, Martin JL, Charca L, Pino M, et al. Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias Study. Front Med (Lausanne). 2021;8: 679009.","journal-title":"Front Med (Lausanne)."},{"issue":"12","key":"2192_CR33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14712598.2022.1998448","volume":"21","author":"R Queiro","year":"2021","unstructured":"Queiro R. Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine? Expert Opin Biol Ther. 2021;21(12):1539\u201341.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"2192_CR34","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","volume":"74","author":"P Hojgaard","year":"2015","unstructured":"Hojgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH, et al. Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2015;74(12):2130\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"2192_CR35","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.3390\/ijms222313004","volume":"22","author":"R Queiro","year":"2021","unstructured":"Queiro R, Coto P, Gonzalez-Lara L, Coto E. Genetic variants of the NF-kappaB pathway: unraveling the genetic architecture of psoriatic disease. Int J Mol Sci. 2021;22(23):13004.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2192_CR36","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2014.123","volume":"134","author":"G Murdaca","year":"2014","unstructured":"Murdaca G, Gulli R, Spano F, Lantieri F, Burlando M, Parodi A, et al. TNF-alpha gene polymorphisms: association with disease susceptibility and response to anti-TNF-alpha treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503\u20139.","journal-title":"J Invest Dermatol"},{"key":"2192_CR37","doi-asserted-by":"crossref","unstructured":"Al-Sofi RF, Bergmann MS, Nielsen CH, Andersen V, Skov L, Loft N. The association between genetics and response to treatment with biologics in patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases: a systematic review and meta-analysis. Int J Mol Sci. 2024;25(11):5793.","DOI":"10.3390\/ijms25115793"},{"issue":"1","key":"2192_CR38","volume":"8","author":"PDK Curry","year":"2024","unstructured":"Curry PDK, Morris AP, Jani M, Chinoy H, Barton A, Bluett J, Collaborators O. Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response. Rheumatol Adv Pract. 2024;8(1): rkae014.","journal-title":"Rheumatol Adv Pract."},{"issue":"12","key":"2192_CR39","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41584-023-01038-9","volume":"19","author":"D McGonagle","year":"2023","unstructured":"McGonagle D, David P, Macleod T, Watad A. Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis. Nat Rev Rheumatol. 2023;19(12):818\u201327.","journal-title":"Nat Rev Rheumatol"},{"key":"2192_CR40","unstructured":"Harland M DP, Wong C, Weddell J, Rao A, Khan A, Timothy J, Loughenbury P, Dunsmuir R, Borse V, MacEachern C, Van der Heuvel A, Chen W, Macleod T, McGonagle D. Comparative immunology of entheseal anchorage sites between spine, hip and knee demonstrates up to 70-fold greater IL-23 induction from axial enthesis bone: a new angle on the failure of IL-23 blockade in ankylosing spondylitis.  [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9)."},{"issue":"9","key":"2192_CR41","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/ced.15237","volume":"47","author":"Y Xie","year":"2022","unstructured":"Xie Y, Liu Y. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12\/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review. Clin Exp Dermatol. 2022;47(9):1627\u201335.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"2192_CR42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","volume":"18","author":"S Tarannum","year":"2022","unstructured":"Tarannum S, Leung YY, Johnson SR, Widdifield J, Strand V, Rochon P, Eder L. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"2192_CR43","doi-asserted-by":"crossref","unstructured":"Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ, et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9(1):e002718.","DOI":"10.1136\/rmdopen-2022-002718"},{"issue":"7","key":"2192_CR44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3899\/jrheum.2024-0016","volume":"51","author":"I Brana","year":"2024","unstructured":"Brana I, Loredo M, Pardo E, Burger S, Fernandez-Breton E, Queiro R. Patients with psoriatic arthritis-related enthesitis and persistence on tofacitinib under real-world conditions. J Rheumatol. 2024;51(7):682\u20136.","journal-title":"J Rheumatol"},{"key":"2192_CR45","doi-asserted-by":"crossref","unstructured":"Brana I, Pardo E, Burger S, Gonzalez Del Pozo P, Alperi M, Queiro R. Treatment retention and safety of ixekizumab in psoriatic arthritis: a real life single-center experience. J Clin Med. 2023;12(2):467.","DOI":"10.3390\/jcm12020467"},{"issue":"1","key":"2192_CR46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","volume":"10","author":"S Singla","year":"2024","unstructured":"Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 2024;10(1): e003809.","journal-title":"RMD Open"},{"issue":"4","key":"2192_CR47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","volume":"9","author":"FM Perrotta","year":"2022","unstructured":"Perrotta FM, Scriffignano S, Ciccia F, Lubrano E. Clinical characteristics of potential \u201cdifficult-to-treat\u201d patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2022;9(4):1193\u2013201.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"2192_CR48","volume":"8","author":"AL Ribeiro","year":"2024","unstructured":"Ribeiro AL, Singla S, Chandran V, Chronis N, Liao W, Lindsay C, et al. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatol Adv Pract. 2024;8(3): rkae074.","journal-title":"Rheumatol Adv Pract."},{"issue":"5","key":"2192_CR49","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol Ther. 2023;10(5):1119\u201325.","journal-title":"Rheumatol Ther."},{"issue":"2","key":"2192_CR50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3899\/jrheum.2023-0177","volume":"51","author":"F Salaffi","year":"2024","unstructured":"Salaffi F, Farah S, Bianchi B, Di Carlo M. Central sensitization in psoriatic arthritis: relationship with composite measures of disease activity, functional disability, and health-related quality of life. J Rheumatol. 2024;51(2):144\u20139.","journal-title":"J Rheumatol"},{"issue":"3","key":"2192_CR51","doi-asserted-by":"crossref","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","volume":"39","author":"N Crispino","year":"2021","unstructured":"Crispino N, Ciccia F. JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2021;39(3):668\u201375.","journal-title":"Clin Exp Rheumatol"},{"key":"2192_CR52","doi-asserted-by":"crossref","first-page":"1331761","DOI":"10.3389\/fmed.2024.1331761","volume":"11","author":"E Toledano","year":"2024","unstructured":"Toledano E, Queiro R, Gomez-Lechon L, Chacon CC, Hidalgo C, Ibanez M, et al. Influence of comorbidities not associated with fibromyalgia on neuropathic pain in patients with psoriatic arthritis: relationship with clinical parameters. Front Med (Lausanne). 2024;11:1331761.","journal-title":"Front Med (Lausanne)."},{"issue":"1","key":"2192_CR53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-024-03396-5","volume":"26","author":"D Currado","year":"2024","unstructured":"Currado D, Saracino F, Ruscitti P, Marino A, Pantano I, Vomero M, et al. Pain catastrophizing negatively impacts drug retention rate in patients with psoriatic arthritis and axial spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study. Arthritis Res Ther. 2024;26(1):162.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2192_CR54","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101970","volume":"38","author":"P Sarzi-Puttini","year":"2024","unstructured":"Sarzi-Puttini P, Pellegrino G, Giorgi V, Bongiovanni SF, Varrassi G, Di Lascio S, et al. Inflammatory or non-inflammatory pain in inflammatory arthritis - How to differentiate it? Best Pract Res Clin Rheumatol. 2024;38(1): 101970.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"2192_CR55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10787-021-00822-x","volume":"29","author":"CM Rocha","year":"2021","unstructured":"Rocha CM, Alves AM, Bettanin BF, Majolo F, Gehringer M, Laufer S, Goettert MI. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. Inflammopharmacology. 2021;29(3):595\u2013615.","journal-title":"Inflammopharmacology"},{"issue":"2","key":"2192_CR56","first-page":"114","volume":"26","author":"SG Tsiogkas","year":"2024","unstructured":"Tsiogkas SG, Dvir YM, Shoenfeld Y, Bogdanos DP. Artificial intelligence and prediction of response to biologics in psoriatic disease using immunophenotype data: a mini review. Isr Med Assoc J. 2024;26(2):114\u20139.","journal-title":"Isr Med Assoc J"},{"key":"2192_CR57","doi-asserted-by":"crossref","first-page":"1759720X2110140","DOI":"10.1177\/1759720X211014010","volume":"13","author":"C Magee","year":"2021","unstructured":"Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review. Ther Adv Musculoskelet Dis. 2021;13:1759720X211014010.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"2","key":"2192_CR58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","volume":"58","author":"I Miyagawa","year":"2019","unstructured":"Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019;58(2):336\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"2192_CR59","volume":"9","author":"I Miyagawa","year":"2022","unstructured":"Miyagawa I, Tanaka Y. Dawn of precision medicine in psoriatic arthritis. Front Med (Lausanne). 2022;9: 851892.","journal-title":"Front Med (Lausanne)."},{"issue":"9","key":"2192_CR60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078539","volume":"13","author":"A Ooms","year":"2023","unstructured":"Ooms A, Al-Mossawi H, Bennett L, Bogale M, Bowness P, Francis A, et al. Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis. BMJ Open. 2023;13(9): e078539.","journal-title":"BMJ Open"},{"issue":"10","key":"2192_CR61","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/jpm12101618","volume":"12","author":"P Tesolin","year":"2022","unstructured":"Tesolin P, Bertinetto FE, Sonaglia A, Cappellani S, Concas MP, Morgan A, et al. High throughput genetic characterisation of caucasian patients affected by multi-drug resistant rheumatoid or psoriatic arthritis. J Pers Med. 2022;12(10):1618.","journal-title":"J Pers Med."},{"issue":"12","key":"2192_CR62","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/exd.13790","volume":"27","author":"MC Ovejero-Benito","year":"2018","unstructured":"Ovejero-Benito MC, Reolid A, Sanchez-Jimenez P, Saiz-Rodriguez M, Munoz-Aceituno E, Llamas-Velasco M, et al. Histone modifications associated with biological drug response in moderate-to-severe psoriasis. Exp Dermatol. 2018;27(12):1361\u201371.","journal-title":"Exp Dermatol"},{"issue":"1","key":"2192_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41397-022-00290-8","volume":"23","author":"PDK Curry","year":"2023","unstructured":"Curry PDK, Morris AP, Barton A, Bluett J. Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis? Pharmacogenomics J. 2023;23(1):1\u20137.","journal-title":"Pharmacogenomics J"},{"key":"2192_CR64","doi-asserted-by":"crossref","first-page":"1054539","DOI":"10.3389\/fimmu.2022.1054539","volume":"13","author":"T Wirth","year":"2022","unstructured":"Wirth T, Balandraud N, Boyer L, Lafforgue P, Pham T. Biomarkers in psoriatic arthritis: a meta-analysis and systematic review. Front Immunol. 2022;13:1054539.","journal-title":"Front Immunol"},{"issue":"6","key":"2192_CR65","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/art.40830","volume":"71","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Qiu J, Lin ZT, Li W, Haley C, Mui UN, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol. 2019;71(6):941\u201351.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2192_CR66","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1093\/rheumatology\/keac197","volume":"61","author":"L Folle","year":"2022","unstructured":"Folle L, Bayat S, Kleyer A, Fagni F, Kapsner LA, Schlereth M, et al. Advanced neural networks for classification of MRI in psoriatic arthritis, seronegative, and seropositive rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4945\u201351.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2192_CR67","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001845","volume":"7","author":"E Pournara","year":"2021","unstructured":"Pournara E, Kormaksson M, Nash P, Ritchlin CT, Kirkham BW, Ligozio G, et al. Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open. 2021;7(3): e001845.","journal-title":"RMD Open"},{"issue":"1","key":"2192_CR68","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-020-2103-8","volume":"22","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020;22(1):18.","journal-title":"Arthritis Res Ther"},{"key":"2192_CR69","doi-asserted-by":"crossref","unstructured":"Borst C, Alasti F, Smolen JS, Aletaha D. Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. RMD Open. 2021;7(3):e002038.","DOI":"10.1136\/rmdopen-2021-002038"},{"issue":"5","key":"2192_CR70","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/art.42780","volume":"76","author":"F Fagni","year":"2024","unstructured":"Fagni F, Motta F, Schett G, Selmi C. Difficult-to-treat psoriatic arthritis: a conceptual approach. Arthritis Rheumatol. 2024;76(5):670\u20134.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"2192_CR71","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/rheumatology\/keae006","volume":"63","author":"CE Gollins","year":"2024","unstructured":"Gollins CE, Vincent R, Fahy C, McHugh N, Brooke M, Tillett W. Effectiveness of sequential lines of biologic and targeted small-molecule drugs in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2024;63(7):1790\u2013802.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2192_CR72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2192_CR73","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/ard-2022-223650","volume":"82","author":"B Glintborg","year":"2023","unstructured":"Glintborg B, Di Giuseppe D, Wallman JK, Nordstrom DC, Gudbjornsson B, Hetland ML, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023;82(6):820.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2192_CR74","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","volume":"40","author":"M Lorenzin","year":"2021","unstructured":"Lorenzin M, Ortolan A, Cozzi G, Calligaro A, Favaro M, Del Ross T, et al. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFalpha, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin Rheumatol. 2021;40(11):4569\u201380.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"2192_CR75","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","volume":"11","author":"LE Kristensen","year":"2024","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Carter K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the phase 3 KEEPsAKE 1 randomized clinical trial. Rheumatol Ther. 2024;11(3):617\u201332.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"2192_CR76","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40744-024-00657-2","volume":"11","author":"A Ostor","year":"2024","unstructured":"Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the KEEPsAKE 2 randomized clinical trial. Rheumatol Ther. 2024;11(3):633\u201348.","journal-title":"Rheumatol Ther."},{"issue":"9","key":"2192_CR77","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/rheumatology\/keae277","volume":"63","author":"L Gossec","year":"2024","unstructured":"Gossec L, Orbai AM, de Wit M, Coates LC, Ogdie A, Ink B, et al. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. Rheumatology (Oxford). 2024;63(9):2399\u2013410.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2192_CR78","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/ard-2023-224431","volume":"82","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, et al. Bimekizumab treatment in biologic DMARD-naive patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023;82(11):1404\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2192_CR79","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10067-022-06218-8","volume":"41","author":"LC Coates","year":"2022","unstructured":"Coates LC, Mease P, Kronbergs A, Helt C, Sandoval D, Park SY, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. Clin Rheumatol. 2022;41(10):3035\u201347.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2192_CR80","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019;5(1): e000808.","journal-title":"RMD Open"},{"issue":"5","key":"2192_CR81","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14712598.2024.2357381","volume":"24","author":"A Spini","year":"2024","unstructured":"Spini A, Pellegrini G, Ingrasciotta Y, L\u2019Abbate L, Bellitto C, Carollo M, et al. Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network. Expert Opin Biol Ther. 2024;24(5):399\u2013409.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2192_CR82","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2020-217209","volume":"80","author":"DA Pappas","year":"2021","unstructured":"Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021;80(1):96\u2013102.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2192_CR83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40259-024-00655-4","volume":"38","author":"HP Cohen","year":"2024","unstructured":"Cohen HP, Bodenmueller W. Additional data in expanded patient populations and new indications support the practice of biosimilar-to-biosimilar switching. BioDrugs. 2024;38(3):331\u20139.","journal-title":"BioDrugs"},{"issue":"1","key":"2192_CR84","volume":"9","author":"CJT van der Togt","year":"2023","unstructured":"van der Togt CJT, Van den Bemt B, Aletaha D, Alten R, Chatzidionysiou K, Galloway J, et al. Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. 2023;9(1): e002898.","journal-title":"RMD Open"},{"issue":"3","key":"2192_CR85","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004389","volume":"10","author":"AC Regierer","year":"2024","unstructured":"Regierer AC, Kiefer D, Schett G, Krause A, Weiss A, Sewerin P, Strangfeld A. No difference in clinical parameters and drug retention in PsA patients receiving b\/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry. RMD Open. 2024;10(3): e004389.","journal-title":"RMD Open"},{"issue":"11","key":"2192_CR86","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00296-018-4144-8","volume":"38","author":"G Deza","year":"2018","unstructured":"Deza G, Notario J, Ferran M, Beltran E, Almirall M, Alcala R, et al. Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain. Rheumatol Int. 2018;38(11):2037\u201343.","journal-title":"Rheumatol Int"},{"issue":"2","key":"2192_CR87","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14095","volume":"54","author":"L Exposito","year":"2024","unstructured":"Exposito L, Sanchez-Piedra C, Vela-Casasempere P, Moreno-Ramos MJ, Campos C, Bohorquez C, et al. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis. Eur J Clin Invest. 2024;54(2): e14095.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2192_CR88","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(22)00329-0","volume":"5","author":"M Koehm","year":"2023","unstructured":"Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jurgens J, Burmester GR, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol. 2023;5(1):e14\u201323.","journal-title":"Lancet Rheumatol."},{"key":"2192_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11727","author":"IB McInnes","year":"2024","unstructured":"McInnes IB, Mease PJ, Tanaka Y, Gossec L, Husni ME, Kristensen LE, et al. Efficacy and Safety of bimekizumab in patients with psoriatic arthritis with or without methotrexate: 52-week results from two phase 3 studies. ACR Open Rheumatol. 2024. https:\/\/doi.org\/10.1002\/acr2.11727.","journal-title":"ACR Open Rheumatol."},{"key":"2192_CR90","doi-asserted-by":"crossref","first-page":"1283251","DOI":"10.3389\/fimmu.2023.1283251","volume":"14","author":"C Valero-Martinez","year":"2023","unstructured":"Valero-Martinez C, Urgelles JF, Salles M, Joven-Ibanez BE, de Juanes A, Ramirez J, et al. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Front Immunol. 2023;14:1283251.","journal-title":"Front Immunol"},{"issue":"5","key":"2192_CR91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105578","volume":"90","author":"MY Mutlu","year":"2023","unstructured":"Mutlu MY, Tascilar K, Schett G. Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis. Joint Bone Spine. 2023;90(5): 105578.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"2192_CR92","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8(4):307\u201320.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"11","key":"2192_CR93","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","volume":"70","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Genovese MC, Weinblatt ME, Peloso PM, Chen K, Othman AA, et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17a-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(11):1778\u201389.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2192_CR94","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1093\/rheumatology\/keab905","volume":"61","author":"P Nash","year":"2022","unstructured":"Nash P, Richette P, Gossec L, Marchesoni A, Ritchlin C, Kato K, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022;61(8):3257\u201368.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2192_CR95","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1573397115666181130094455","volume":"15","author":"S Metyas","year":"2019","unstructured":"Metyas S, Tomassian C, Messiah R, Gettas T, Chen C, Quismorio A. Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis. Curr Rheumatol Rev. 2019;15(3):234\u20137.","journal-title":"Curr Rheumatol Rev"},{"issue":"6 Suppl 1","key":"2192_CR96","first-page":"S19","volume":"15","author":"A Martin","year":"2022","unstructured":"Martin A, Thatiparthi A, Liu J, Wu JJ. Interleukin-17 inhibitor combination therapies for the treatment of psoriasis: a systematic review. J Clin Aesthet Dermatol. 2022;15(6 Suppl 1):S19\u201331.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"6","key":"2192_CR97","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s12325-022-02084-7","volume":"39","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A. Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States Healthcare claims database. Adv Ther. 2022;39(6):2932\u201345.","journal-title":"Adv Ther"},{"key":"2192_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222415","author":"D Simon","year":"2022","unstructured":"Simon D, Fagni F, Schett G. Sequential interleukin-17\/interleukin-23 inhibition in treatment-refractory psoriatic arthritis. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222415.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2192_CR99","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003279","volume":"9","author":"A Denis","year":"2023","unstructured":"Denis A, Sztejkowski C, Arnaud L, Becker G, Felten R. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. RMD Open. 2023;9(3): e003279.","journal-title":"RMD Open"},{"issue":"2","key":"2192_CR100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard-2024-226385","volume":"84","author":"J Liu","year":"2025","unstructured":"Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, et al. Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis. 2025;84(2):188\u2013200.","journal-title":"Ann Rheum Dis"},{"key":"2192_CR101","doi-asserted-by":"crossref","unstructured":"Carmona-Rocha E, Rusinol L, Puig L. New and emerging oral\/topical small-molecule treatments for psoriasis. Pharmaceutics. 2024;16(2):239.","DOI":"10.3390\/pharmaceutics16020239"},{"issue":"6","key":"2192_CR102","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2192_CR103","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/art.42921","volume":"76","author":"O FitzGerald","year":"2024","unstructured":"FitzGerald O, Gladman DD, Mease PJ, Ritchlin C, Smolen JS, Gao L, et al. Phase 2 trial of deucravacitinib in psoriatic arthritis: biomarkers associated with disease activity, pharmacodynamics, and clinical responses. Arthritis Rheumatol. 2024;76(9):1397\u2013407.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2192_CR104","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","volume":"13","author":"G Martin","year":"2023","unstructured":"Martin G. Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors. Dermatol Ther (Heidelb). 2023;13(2):417\u201335.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"2192_CR105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/annrheumdis-2024-eular.351","volume":"83","author":"AME Kivitz","year":"2024","unstructured":"Kivitz AME, Kavanaugh A, et al. OP0138 efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis. Ann Rheum Dis. 2024;83:149\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2192_CR106","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr.22107","volume":"66","author":"LE Kristensen","year":"2014","unstructured":"Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gulfe A, Saxne T, Geborek P. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. Arthritis Care Res (Hoboken). 2014;66(2):173\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"2192_CR107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180014","volume":"12","author":"S Rifbjerg-Madsen","year":"2017","unstructured":"Rifbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML, Bliddal H, Kristensen LE, et al. Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey. PLoS ONE. 2017;12(7): e0180014.","journal-title":"PLoS ONE"},{"issue":"4","key":"2192_CR108","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003570","volume":"9","author":"L Pina Vegas","year":"2023","unstructured":"Pina Vegas L, Penso L, Sbidian E, Claudepierre P. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9(4): e003570.","journal-title":"RMD Open"},{"key":"2192_CR109","doi-asserted-by":"crossref","first-page":"1395968","DOI":"10.3389\/fimmu.2024.1395968","volume":"15","author":"PP Strunz","year":"2024","unstructured":"Strunz PP, Englbrecht M, Risser LM, Witte T, Froehlich M, Schmalzing M, et al. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12\/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database. Front Immunol. 2024;15:1395968.","journal-title":"Front Immunol"},{"issue":"6","key":"2192_CR110","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/rheumatology\/kead434","volume":"63","author":"RL Hansen","year":"2024","unstructured":"Hansen RL, Jorgensen TS, Egeberg A, Roseno NAL, Skougaard M, Stisen ZR, et al. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study. Rheumatology (Oxford). 2024;63(6):1593\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"2192_CR111","unstructured":"Guimaraes F, Ferreira M, Soares C, Parente H, Matos CO, Costa R, et al. Cycling versus swapping strategies in psoriatic arthritis: results from the rheumatic diseases Portuguese register. ARP Rheumatol. 2023. Online ahead of print."},{"issue":"2","key":"2192_CR112","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/03009742.2023.2258644","volume":"53","author":"C Roseman","year":"2024","unstructured":"Roseman C, Wallman JK, Joud A, Schelin M, Einarsson JT, Lindqvist E, et al. Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control? Scand J Rheumatol. 2024;53(2):94\u2013103.","journal-title":"Scand J Rheumatol"},{"key":"2192_CR113","doi-asserted-by":"crossref","unstructured":"Samuel C, Finney A, Grader-Beck T, Haque U, Miller J, Grieb SM, et al. Characteristics associated with patient-reported treatment success in psoriatic arthritis. Rheumatology (Oxford). 2025;64(3):1111\u201321.","DOI":"10.1093\/rheumatology\/keae149"},{"issue":"7","key":"2192_CR114","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11926-024-01146-9","volume":"26","author":"AL Ribeiro","year":"2024","unstructured":"Ribeiro AL, Eder L. From psoriasis to psoriatic arthritis: ultrasound insights connecting psoriasis with subclinical musculoskeletal inflammation and the path to psoriatic arthritis. Curr Rheumatol Rep. 2024;26(7):235\u201347.","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"2192_CR115","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3899\/jrheum.181385","volume":"47","author":"PS Helliwell","year":"2020","unstructured":"Helliwell PS, Coates LC, Chew NS, Lettieri G, Moverley AR, Freeston JE, et al. Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound, and clinical outcomes: data from the TICOPA trial. J Rheumatol. 2020;47(9):1338\u201343.","journal-title":"J Rheumatol"},{"issue":"3","key":"2192_CR116","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003339","volume":"9","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, de Vlam K, Ronga M, Perrotta FM, Lories R. Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise - a review. RMD Open. 2023;9(3): e003339.","journal-title":"RMD Open"},{"issue":"1","key":"2192_CR117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10787-022-01092-x","volume":"31","author":"A Makos","year":"2023","unstructured":"Makos A, Kuiper JH, Kehoe O, Amarasena R. Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors. Inflammopharmacology. 2023;31(1):77\u201387.","journal-title":"Inflammopharmacology"},{"issue":"2","key":"2192_CR118","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001600","volume":"7","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Landewe R, Rahman P, Tahir H, Singhal A, Boettcher E, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021;7(2): e001600.","journal-title":"RMD Open"},{"issue":"5","key":"2192_CR119","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"2192_CR120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landewe R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38\u201348.","journal-title":"Lancet"},{"issue":"1","key":"2192_CR121","doi-asserted-by":"crossref","first-page":"2342383","DOI":"10.1080\/09546634.2024.2342383","volume":"35","author":"JF Merola","year":"2024","unstructured":"Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35(1):2342383.","journal-title":"J Dermatolog Treat"},{"issue":"10230","key":"2192_CR122","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"1","key":"2192_CR123","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","volume":"21","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1\u20133 pooled analysis. Arthritis Res Ther. 2019;21(1):118.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2192_CR124","first-page":"275","volume":"10","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Haaland D, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther. 2023;10(1):275\u201392.","journal-title":"Rheumatol Ther."},{"issue":"3","key":"2192_CR125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2192_CR126","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ramirez J, Canete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901.","journal-title":"Int J Mol Sci"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02192-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02192-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02192-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:52Z","timestamp":1750694152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02192-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":126,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02192-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]},"assertion":[{"value":"16 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The medical writing assistance was supported by UCB Espa\u00f1a, who did not influence any aspect of the study design, data collection, analysis or interpretation, or the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R.Q. has received payment for scientific consultancy, research projects, conferences, attendance at meetings and congresses, and training activities, from Abbvie, Amgen, Eli-Lilly,\u00a0Johnson & Johnson,\u00a0MSD, Novartis, Pfizer and UCB. He has also received unrestricted grants for research from Abbvie, Novartis,\u00a0Johnson & Johnson and UCB. J.P.T. has received consulting and advisory board fees and research grants from Bristol Myers Squibb, Celgene, AbbVie, BMS, Janssen, Novartis, Pfizer and UCB. C.M.M. has received payment for training activities from Amgen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"R.Q. is responsible for the conceptualisation and design of the review, critically reviewing and revising all drafts of the review, and approving the final version of the manuscript. J.A.P.T. and C.M.M. critically reviewed and revised all drafts of the manuscript and approved the final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data availability is not applicable to this article as no new data were generated or analysed in this narrative review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable as the manuscript does not include identifiable human data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable as the manuscript does not include identifiable human data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable to this review article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}